Clinical Trials Logo

Clinical Trial Summary

SC-43 is STAT3 inhibitor. Based on the phase I data of SC-43 monotherapy, this is a Phase 1/2, Open-label, Study to Investigate the Safety, Tolerability, and Efficacy of SC-43 Administered in Combination with Cisplatin in Subjects with Advanced or Refractory Non-small Cell Lung Cancer or Biliary Tract Carcinoma


Clinical Trial Description

Based on the ongoing Phase 1 study in refractory cancer types, it is deemed adequate to select the starting dose at 50 mg in combination with cisplatin for NSCLC or BTC. The safety monitoring committee (SMC) will review the starting dose of 50 mg data and decide whether it is adequate to escalate the dose to 100, then 150 mg according to Bayesian optimal interval (BOIN) design. Moreover, based on the PK profiles and modelling, the loading dose 100 mg QD for 7 days will keep the minimal efficacy concentration and effectively maintain the p-STAT3 level low enough to translate the anticancer efficacy with clinical efficacy for the study drug SC-43. The cisplatin efficacy for NSCLC and BTC, the chosen dose and dosing schedules 75 mg/m2 in a 3-week cycle in combination with SC-43 are supported by previous clinical experience of observed efficacy and safety profiles for the indicated study populations. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT04733521
Study type Interventional
Source RaND Biosciences
Contact Chief Clinical Officer
Phone 82 70 7005 6875
Email ahn@randbio.com
Status Not yet recruiting
Phase Phase 1/Phase 2
Start date May 1, 2021
Completion date September 30, 2023

See also
  Status Clinical Trial Phase
Not yet recruiting NCT05009953 - Study of Irinotecan Liposome Injection in Patients With Advanced Biliary Tract Cancer Phase 2
Recruiting NCT05820906 - Cadonilimab Plus Regorafenib and Gem-Cis Chemotherapy in Advanced Biliary Tract Cancer Phase 2
Completed NCT03358849 - Phase 1 Clinical Trial to Evaluate the Safety of Allogeneic NK Cell ("SMT-NK") Cell Therapy in Advanced Biliary Tract Cancer Phase 1
Recruiting NCT05410197 - Envofolimab and Lenvatinib Combined With Gemcitabine Plus Cisplatin for Advanced BTC as First-Line Treatment(ENLIGHTEN) Phase 2
Active, not recruiting NCT04727996 - Phase II Study of Sitravatinib in Combination With Tislelizumab in Patients With Advanced Biliary Tract Cancer Phase 2
Recruiting NCT05823987 - Oncolytic Virotherapy Combined With Tislelizumab Plus Lenvatinib in Patients With Advanced Biliary Tract Cancer (OPTIONS-05) Phase 2
Recruiting NCT04027764 - Toripalimab Combined With S1 and Albumin Paclitaxel in Patients With Advanced Biliary Tract Cancer Phase 2
Recruiting NCT05781074 - Cryoablation Combined With Sintilimab Plus Lenvatinib in Patients With Immune Checkpoint Inhibitor Previously Treated Advanced Biliary Tract Cancer (CASTLE-08) Phase 2
Recruiting NCT04781192 - The Purpose of This Trial is to Determine if Regorafenib Plus Durvalumab (MEDI4736) is Safe and Effective in Treatment of Chemo Refractory Advanced Biliary Tract Cancers Phase 1/Phase 2
Recruiting NCT05653180 - IBI310 in Combination With Sintilimab in Patients With Advanced Biliary Tract Cancer Phase 1/Phase 2
Recruiting NCT04005339 - NAPOLI-2: Fluorouracil, Leucovorin, and Nanoliposomal Irinotecan in Biliary Cancer Phase 2
Completed NCT04217954 - HAIC With Oxaliplatin, 5-FU and Bevacizumab Plus Intravenous Toripalimab for Advanced BTC Phase 2
Recruiting NCT05170438 - Lenvatinib Plus Paclitaxel for Patients With Advanced Biliary Tract Cancer Who Failed to Gemcitabine-based Treatment Phase 2
Active, not recruiting NCT04172402 - NGS as the First-line Treatment in Advanced Biliary Tract Cancer Phase 2
Withdrawn NCT02597465 - A Randomized, Open-Label, Comparative, Parallel-Group, Multicenter Study of SPARC1507 Phase 3
Active, not recruiting NCT04969887 - Combination Immunotherapy in Rare Cancers Under InvesTigation Phase 2
Recruiting NCT04211168 - Toripalimab Plus Lenvatinib as Second-line Treatment in Advanced Biliary Tract Cancers Phase 2
Recruiting NCT05812430 - Anlotinib Plus TQB2450 Combined With Nab-paclitaxel and Cisplatin as First-line Treatment for Advanced Biliary Tract Cancer Phase 2